Mohd Basri Mat Nor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mohd Basri Mat Nor has a total of 561 co-authors. Here are the top co-authors by number of shared publications:
Azrina Md Ralib
Department of Anaesthesiology and Critical Care, Kuliyyah of Medicine, International Islamic Universiti Malaysia, Pahang, Malaysia
16 shared publications- Azrina Md Ralib
Department of Anaesthesiology and Intensive Care, Kulliyyah of Medicine, International Islamic University Malaysia, Pahang, Malaysia
12 shared publications - Yeong Shiong Chiew
School of Engineering, Monash University Malaysia, Selangor, Malaysia
11 shared publications - Ummu Khulthum Jamaludin
Universiti Malaysia Pahang
7 shared publications Wan Fadzlina Wan Muhd Shukeri
Department of Anaesthesiology and Intensive Care, School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia
7 shared publicationsAzrina Md. Ralib
6 shared publications
Latest Publications
- Open Access
- 13 October 2026
- Published by Elsevier in SSRN Electronic Journal
Antimicrobial Utilisation, Resistance Rates, And Factors Associated With Antimicrobial Density In Intensive Care Units: A Registry Enabled, Prospective Evaluation Of 129 Low, Lower-Middle And Upper Middle Income Country ICUs
Background: Antimicrobial resistance (AMR) causes an estimated one million deaths annually, with critically ill patients particularly vulnerable due to immune compromise and secondary infections. Antimicrobial use drives AMR and is especially high in Intensive Care Units (ICUs), which have elevated rates of hospital-associated and drug-resistant infections. This study aimed to describe antimicrobial use and resistance in ICUs in low- and lower-middle-income countries (LMICs) and identify ICU-level factors associated with increased use.Methods: Data were drawn from 129 ICUs across 11 LMICs participating in a registry antimicrobial surveillance project. Demographics, clinical data, and antimicrobial prescribing metrics, including prescribing rate (APR), and antimicrobial density (AD), were collected using WHO surveillance definitions and WHO AWARE classification. Infection, organism, and resistance data were analysed with ICU-level structural and microbiology practice data, and were reported for the whole ICU cohort, and by ICU subspecialty. Adjusted analysis identified factors associated with increased AD.Findings: Over 12 months from Jan–Dec 2023, 47,938 ICU patients were recruited. Median APR was 94.3% (IQR 86.7–99.2); median duration of therapy was 3 days (IQR 2–5); and median AD was 1163 per 1000 patient-days (IQR 914–1466). Dual and triple therapy was prescribed in 40% of patients within 24 hours of ICU admission. WHO 'Watch' list drugs made up 66.6% of all prescriptions and 74.7% on ICU Day one. Direct onsite microbiological laboratory access was reported by 91.5% of ICUs. Median ICU culture rates were at 10.8% (IQR 1.3–24.7), and median ICU stay to culture being taken was 4 days. Among cultures reported, growth was reported in 33.3% (8-57.9), of which, 80% identified at least one resistant organism. Mechanical ventilation (MV) (RR 1.01, 95% CI 1.007–1.014) was positively associated with AD. AD was lower in low- and upper-middle-income countries compared to lower-middle-income country ICUs.Interpretation: Antimicrobial use was high across ICUs with early use of broad-spectrum (‘Watch’/ ‘Reserve’) agents and frequent polypharmacy, often without early microbiological guidance suggesting that clinicians may assume drug resistant infection from admission. Culture use appeared delayed and not clearly linked to laboratory availability. Antimicrobial density was associated with mechanical ventilation and varied by country income level.
- 13 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessAntimicrobial Utilisation, Resistance Rates, And Factors Associated With Antimicrobial Density In Intensive Care Units: A Registry Enabled, Prospective Evaluation Of 129 Low, Lower-Middle And Upper Middle Income Country ICUs
Background: Antimicrobial resistance (AMR) causes an estimated one million deaths annually, with critically ill patients particularly vulnerable due to immune compromise and secondary infections. Antimicrobial use drives AMR and is especially high in Intensive Care Units (ICUs), which have elevated rates of hospital-associated and drug-resistant infections. This study aimed to describe antimicrobial use and resistance in ICUs in low- and lower-middle-income countries (LMICs) and identify ICU-level factors associated with increased use.Methods: Data were drawn from 129 ICUs across 11 LMICs participating in a registry antimicrobial surveillance project. Demographics, clinical data, and antimicrobial prescribing metrics, including prescribing rate (APR), and antimicrobial density (AD), were collected using WHO surveillance definitions and WHO AWARE classification. Infection, organism, and resistance data were analysed with ICU-level structural and microbiology practice data, and were reported for the whole ICU cohort, and by ICU subspecialty. Adjusted analysis identified factors associated with increased AD.Findings: Over 12 months from Jan–Dec 2023, 47,938 ICU patients were recruited. Median APR was 94.3% (IQR 86.7–99.2); median duration of therapy was 3 days (IQR 2–5); and median AD was 1163 per 1000 patient-days (IQR 914–1466). Dual and triple therapy was prescribed in 40% of patients within 24 hours of ICU admission. WHO 'Watch' list drugs made up 66.6% of all prescriptions and 74.7% on ICU Day one. Direct onsite microbiological laboratory access was reported by 91.5% of ICUs. Median ICU culture rates were at 10.8% (IQR 1.3–24.7), and median ICU stay to culture being taken was 4 days. Among cultures reported, growth was reported in 33.3% (8-57.9), of which, 80% identified at least one resistant organism. Mechanical ventilation (MV) (RR 1.01, 95% CI 1.007–1.014) was positively associated with AD. AD was lower in low- and upper-middle-income countries compared to lower-middle-income country ICUs.Interpretation: Antimicrobial use was high across ICUs with early use of broad-spectrum (‘Watch’/ ‘Reserve’) agents and frequent polypharmacy, often without early microbiological guidance suggesting that clinicians may assume drug resistant infection from admission. Culture use appeared delayed and not clearly linked to laboratory availability. Antimicrobial density was associated with mechanical ventilation and varied by country income level.
- Open Access
- 11 July 2026
- Published by Elsevier in American Journal of Infection Control
- Vol. 54 (12) , 1271-1276
Prospective multicenter multinational cohort study: Time-to-central line-associated bloodstream infection with plain vs chlorhexidine/silver sulfadiazine impregnated central venous catheters
- 11 July 2026
- Published by Elsevier in American Journal of Infection Control
- Vol. 54 (12) , 1271-1276
Open AccessProspective multicenter multinational cohort study: Time-to-central line-associated bloodstream infection with plain vs chlorhexidine/silver sulfadiazine impregnated central venous catheters
- Top Cited PapersOpen Access
- 3 February 2025
- Published by Springer Nature in Intensive Care Medicine
- Vol. 51 (2) , 302-317
Are contemporary antifungal doses sufficient for critically ill patients? Outcomes from an international, multicenter pharmacokinetics study for Screening Antifungal Exposure in Intensive Care Units—the SAFE-ICU study
Purpose Appropriate antifungal therapy is a major determinant of survival in critically ill patients with invasive fungal disease. We sought to describe whether contemporary dosing of antifungals achieves therapeutic exposures in critically ill patients. Methods In a prospective, open-label, multicenter pharmacokinetic study, intensive care unit (ICU) patients prescribed azoles, echinocandins, or polyene antifungals for treatment or prophylaxis of invasive fungal disease were enrolled. Blood samples were collected on two occasions, with three samples taken during a single dosing interval on each occasion. Total concentrations were centrally measured using validated chromatographic methods. Pharmacokinetic parameters were estimated using noncompartmental methods. Antifungal dosing adequacy was assessed using predefined PK/PD targets. Results We included 339 patients from 30 ICUs across 12 countries. Median age 62 (interquartile range [IQR], 51–70) years, median APACHE II score 22 (IQR, 17–28), and 61% males. Antifungal therapy was primarily prescribed for treatment (80.8%). Fluconazole was the most frequently prescribed antifungal (40.7%). The most common indication for treatment was intra-abdominal infection (30.7%). Fungi were identified in 45% of patients, of which only 26% had a minimum inhibitory concentration available. Target attainment was higher for patients receiving prophylaxis (> 80% for most drugs). For patients receiving treatment, low target attainment was noted for voriconazole (57.1%), posaconazole (63.2%), micafungin (64.1%) and amphotericin B (41.7%). Conclusion This study highlights the varying degrees of target attainment across antifungal agents in critically ill patients. While a significant proportion of patients achieved the predefined PK/PD targets, wide variability and subtherapeutic exposures persist. Trial registration ClinicalTrials.gov Identifier: NCT03136926, 2017-04-21.
- 3 February 2025
- Published by Springer Nature in Intensive Care Medicine
- Vol. 51 (2) , 302-317
Top Cited PapersOpen AccessAre contemporary antifungal doses sufficient for critically ill patients? Outcomes from an international, multicenter pharmacokinetics study for Screening Antifungal Exposure in Intensive Care Units—the SAFE-ICU study
Purpose Appropriate antifungal therapy is a major determinant of survival in critically ill patients with invasive fungal disease. We sought to describe whether contemporary dosing of antifungals achieves therapeutic exposures in critically ill patients. Methods In a prospective, open-label, multicenter pharmacokinetic study, intensive care unit (ICU) patients prescribed azoles, echinocandins, or polyene antifungals for treatment or prophylaxis of invasive fungal disease were enrolled. Blood samples were collected on two occasions, with three samples taken during a single dosing interval on each occasion. Total concentrations were centrally measured using validated chromatographic methods. Pharmacokinetic parameters were estimated using noncompartmental methods. Antifungal dosing adequacy was assessed using predefined PK/PD targets. Results We included 339 patients from 30 ICUs across 12 countries. Median age 62 (interquartile range [IQR], 51–70) years, median APACHE II score 22 (IQR, 17–28), and 61% males. Antifungal therapy was primarily prescribed for treatment (80.8%). Fluconazole was the most frequently prescribed antifungal (40.7%). The most common indication for treatment was intra-abdominal infection (30.7%). Fungi were identified in 45% of patients, of which only 26% had a minimum inhibitory concentration available. Target attainment was higher for patients receiving prophylaxis (> 80% for most drugs). For patients receiving treatment, low target attainment was noted for voriconazole (57.1%), posaconazole (63.2%), micafungin (64.1%) and amphotericin B (41.7%). Conclusion This study highlights the varying degrees of target attainment across antifungal agents in critically ill patients. While a significant proportion of patients achieved the predefined PK/PD targets, wide variability and subtherapeutic exposures persist. Trial registration ClinicalTrials.gov Identifier: NCT03136926, 2017-04-21.
- Open Access
- 28 November 2024
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 9, 699
Suitability of low and middle-income country data-derived prognostics models for benchmarking mortality in a multinational Asia critical care registry network: a multicentre study
Background This study evaluates the predictive performance of prognostic models derived from low- and middle-income country (LMIC) data using a multinational Asian critical care dataset. The research also seeks to identify opportunities for improving these models' accuracy and utility in clinical research and for international benchmarking of critical care outcomes Methods This retrospective multicenter study evaluated the performance of four prognostic models: e-Tropical Intensive Care Score (e-TropICS), Tropical Intensive Care Score (TropICS), Simplified Mortality Score for the Intensive Care Unit (SMS-ICU), and Rwanda Mortality Probability Model (R-MPM) using a dataset of 64,327 ICU admissions from 109 ICUs across six Asian countries. The models' discriminative abilities were assessed using ROC curves, and calibration was evaluated with Hosmer-Lemeshow C-statistics and calibration curves. Recalibration was performed to improve model accuracy, and the impact of the COVID-19 pandemic on model performance was also analysed. Results The e-TropICS and R-MPM models showed relatively good discriminative power, with AUCs of 0.71 and 0.69, respectively. However, all models exhibited significant calibration issues, particularly at higher predicted probabilities, even after recalibration. The study also revealed variability in model performance across different countries, with India's data demonstrating the highest discriminative power. Conclusions The study highlights the challenges of applying existing prognostic models in diverse ICU settings, particularly in LMICs. While the e-TropICS and R-MPM models performed relatively well, significant calibration issues indicate a need for further refinement. Future efforts should focus on developing adaptable models that can effectively accommodate the diverse and dynamic nature of ICU populations worldwide, ensuring their utility in global healthcare benchmarking and decision-making.
- 28 November 2024
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 9, 699
Open AccessSuitability of low and middle-income country data-derived prognostics models for benchmarking mortality in a multinational Asia critical care registry network: a multicentre study
Background This study evaluates the predictive performance of prognostic models derived from low- and middle-income country (LMIC) data using a multinational Asian critical care dataset. The research also seeks to identify opportunities for improving these models' accuracy and utility in clinical research and for international benchmarking of critical care outcomes Methods This retrospective multicenter study evaluated the performance of four prognostic models: e-Tropical Intensive Care Score (e-TropICS), Tropical Intensive Care Score (TropICS), Simplified Mortality Score for the Intensive Care Unit (SMS-ICU), and Rwanda Mortality Probability Model (R-MPM) using a dataset of 64,327 ICU admissions from 109 ICUs across six Asian countries. The models' discriminative abilities were assessed using ROC curves, and calibration was evaluated with Hosmer-Lemeshow C-statistics and calibration curves. Recalibration was performed to improve model accuracy, and the impact of the COVID-19 pandemic on model performance was also analysed. Results The e-TropICS and R-MPM models showed relatively good discriminative power, with AUCs of 0.71 and 0.69, respectively. However, all models exhibited significant calibration issues, particularly at higher predicted probabilities, even after recalibration. The study also revealed variability in model performance across different countries, with India's data demonstrating the highest discriminative power. Conclusions The study highlights the challenges of applying existing prognostic models in diverse ICU settings, particularly in LMICs. While the e-TropICS and R-MPM models performed relatively well, significant calibration issues indicate a need for further refinement. Future efforts should focus on developing adaptable models that can effectively accommodate the diverse and dynamic nature of ICU populations worldwide, ensuring their utility in global healthcare benchmarking and decision-making.
- Open Access
- 31 August 2024
- Published by The Korean Society of Critical Care Medicine in Acute and Critical Care
- Vol. 39 (3) , 390-399
The impact of age on mortality in the intensive care unit: a retrospective cohort study in Malaysia
Background: Age is a significant consideration for intensive care unit (ICU) admission. However, the reported associations between increasing age and mortality vary across studies, and data in the local context of Malaysia are lacking. The objective of the present study was to determine the impact of increasing age on ICU mortality. Methods: A retrospective cohort study of ICU patients was conducted between January 2020 and November 2023 at a university hospital in Malaysia. Patients were classified into two categories according to age (years) and into four groups according to National Library of Medicine Medical Subject Headings (MeSH): young adult (19–24), adult (25–44), middle age (45–64) and elderly (≥65). The Cochran-Armitage test for trend and Cox proportional hazards regression analyses were performed to evaluate the impact of increasing age on ICU mortality.Results: A total of 1,661 patients was analyzed. The Cochran-Armitage test showed a significant positive association between ICU mortality rate and age group (Z= −4.86, P<0.01) or MeSH category (Z=−5.36, P<0.01). After adjusting for other confounders, the strongest predictor for ICU mortality in the Cox proportional hazards regression analyses was age, with the elderly age group having the highest adjusted hazard ratio of 4.777 (95% confidence interval, 1.128–20.231; P=0.03).Conclusions: Age had a significant impact on ICU mortality in our cohort of critically ill patients.
- 31 August 2024
- Published by The Korean Society of Critical Care Medicine in Acute and Critical Care
- Vol. 39 (3) , 390-399
Open AccessThe impact of age on mortality in the intensive care unit: a retrospective cohort study in Malaysia
Background: Age is a significant consideration for intensive care unit (ICU) admission. However, the reported associations between increasing age and mortality vary across studies, and data in the local context of Malaysia are lacking. The objective of the present study was to determine the impact of increasing age on ICU mortality. Methods: A retrospective cohort study of ICU patients was conducted between January 2020 and November 2023 at a university hospital in Malaysia. Patients were classified into two categories according to age (years) and into four groups according to National Library of Medicine Medical Subject Headings (MeSH): young adult (19–24), adult (25–44), middle age (45–64) and elderly (≥65). The Cochran-Armitage test for trend and Cox proportional hazards regression analyses were performed to evaluate the impact of increasing age on ICU mortality.Results: A total of 1,661 patients was analyzed. The Cochran-Armitage test showed a significant positive association between ICU mortality rate and age group (Z= −4.86, P<0.01) or MeSH category (Z=−5.36, P<0.01). After adjusting for other confounders, the strongest predictor for ICU mortality in the Cox proportional hazards regression analyses was age, with the elderly age group having the highest adjusted hazard ratio of 4.777 (95% confidence interval, 1.128–20.231; P=0.03).Conclusions: Age had a significant impact on ICU mortality in our cohort of critically ill patients.
- 4 January 2024
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 45 (5) , 567-575
Incidence and risk factors for catheter-associated urinary tract infection in 623 intensive care units throughout 37 Asian, African, Eastern European, Latin American, and Middle Eastern nations: A multinational prospective research of INICC
Objective: To identify urinary catheter (UC)–associated urinary tract infection (CAUTI) incidence and risk factors.Design: A prospective cohort study.Setting: The study was conducted across 623 ICUs of 224 hospitals in 114 cities in 37 African, Asian, Eastern European, Latin American, and Middle Eastern countries.Participants: The study included 169,036 patients, hospitalized for 1,166,593 patient days.Methods: Data collection took place from January 1, 2014, to February 12, 2022. We identified CAUTI rates per 1,000 UC days and UC device utilization (DU) ratios stratified by country, by ICU type, by facility ownership type, by World Bank country classification by income level, and by UC type. To estimate CAUTI risk factors, we analyzed 11 variables using multiple logistic regression.Results: Participant patients acquired 2,010 CAUTIs. The pooled CAUTI rate was 2.83 per 1,000 UC days. The highest CAUTI rate was associated with the use of suprapubic catheters (3.93 CAUTIs per 1,000 UC days); with patients hospitalized in Eastern Europe (14.03) and in Asia (6.28); with patients hospitalized in trauma (7.97), neurologic (6.28), and neurosurgical ICUs (4.95); with patients hospitalized in lower–middle-income countries (3.05); and with patients in public hospitals (5.89).The following variables were independently associated with CAUTI: Age (adjusted odds ratio [aOR], 1.01; P < .0001), female sex (aOR, 1.39; P < .0001), length of stay (LOS) before CAUTI-acquisition (aOR, 1.05; P < .0001), UC DU ratio (aOR, 1.09; P < .0001), public facilities (aOR, 2.24; P < .0001), and neurologic ICUs (aOR, 11.49; P < .0001).Conclusions: CAUTI rates are higher in patients with suprapubic catheters, in middle-income countries, in public hospitals, in trauma and neurologic ICUs, and in Eastern European and Asian facilities.Based on findings regarding risk factors for CAUTI, focus on reducing LOS and UC utilization is warranted, as well as implementing evidence-based CAUTI-prevention recommendations.
- 4 January 2024
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 45 (5) , 567-575
Incidence and risk factors for catheter-associated urinary tract infection in 623 intensive care units throughout 37 Asian, African, Eastern European, Latin American, and Middle Eastern nations: A multinational prospective research of INICC
Objective: To identify urinary catheter (UC)–associated urinary tract infection (CAUTI) incidence and risk factors.Design: A prospective cohort study.Setting: The study was conducted across 623 ICUs of 224 hospitals in 114 cities in 37 African, Asian, Eastern European, Latin American, and Middle Eastern countries.Participants: The study included 169,036 patients, hospitalized for 1,166,593 patient days.Methods: Data collection took place from January 1, 2014, to February 12, 2022. We identified CAUTI rates per 1,000 UC days and UC device utilization (DU) ratios stratified by country, by ICU type, by facility ownership type, by World Bank country classification by income level, and by UC type. To estimate CAUTI risk factors, we analyzed 11 variables using multiple logistic regression.Results: Participant patients acquired 2,010 CAUTIs. The pooled CAUTI rate was 2.83 per 1,000 UC days. The highest CAUTI rate was associated with the use of suprapubic catheters (3.93 CAUTIs per 1,000 UC days); with patients hospitalized in Eastern Europe (14.03) and in Asia (6.28); with patients hospitalized in trauma (7.97), neurologic (6.28), and neurosurgical ICUs (4.95); with patients hospitalized in lower–middle-income countries (3.05); and with patients in public hospitals (5.89).The following variables were independently associated with CAUTI: Age (adjusted odds ratio [aOR], 1.01; P < .0001), female sex (aOR, 1.39; P < .0001), length of stay (LOS) before CAUTI-acquisition (aOR, 1.05; P < .0001), UC DU ratio (aOR, 1.09; P < .0001), public facilities (aOR, 2.24; P < .0001), and neurologic ICUs (aOR, 11.49; P < .0001).Conclusions: CAUTI rates are higher in patients with suprapubic catheters, in middle-income countries, in public hospitals, in trauma and neurologic ICUs, and in Eastern European and Asian facilities.Based on findings regarding risk factors for CAUTI, focus on reducing LOS and UC utilization is warranted, as well as implementing evidence-based CAUTI-prevention recommendations.
- Open Access
- 11 December 2023
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 44, 100982
Critical care bed capacity in Asian countries and regions before and during the COVID-19 pandemic: an observational study
- 11 December 2023
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 44, 100982
Open AccessCritical care bed capacity in Asian countries and regions before and during the COVID-19 pandemic: an observational study
- Open Access
- 1 November 2023
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 8, 29
Mixed methods study protocol for combining stakeholder-led rapid evaluation with near real-time continuous registry data to facilitate evaluations of quality of care in intensive care units
Background Improved access to healthcare in low- and middle-income countries (LMICs) has not equated to improved health outcomes. Absence or unsustained quality of care is partly to blame. Improving outcomes in intensive care units (ICUs) requires delivery of complex interventions by multiple specialties working in concert, and the simultaneous prevention of avoidable harms associated with the illness and the treatment interventions. Therefore, successful design and implementation of improvement interventions requires understanding of the behavioural, organisational, and external factors that determine care delivery and the likelihood of achieving sustained improvement. We aim to identify care processes that contribute to suboptimal clinical outcomes in ICUs located in LMICs and to establish barriers and enablers for improving the care processes. Methods Using rapid evaluation methods, we will use four data collection methods: 1) registry embedded indicators to assess quality of care processes and their associated outcomes; 2) process mapping to provide a preliminary framework to understand gaps between current and desired care practices; 3) structured observations of processes of interest identified from the process mapping and; 4) focus group discussions with stakeholders to identify barriers and enablers influencing the gap between current and desired care practices. We will also collect self-assessments of readiness for quality improvement. Data collection and analysis will be led by local stakeholders, performed in parallel and through an iterative process across eight countries: Kenya, India, Malaysia, Nepal, Pakistan, South Africa, Uganda and Vietnam. Conclusions The results of our study will provide essential information on where and how care processes can be improved to facilitate better quality of care to critically ill patients in LMICs; thus, reduce preventable mortality and morbidity in ICUs. Furthermore, understanding the rapid evaluation methods that will be used for this study will allow other researchers and healthcare professionals to carry out similar research in ICUs and other health services.
- 1 November 2023
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 8, 29
Open AccessMixed methods study protocol for combining stakeholder-led rapid evaluation with near real-time continuous registry data to facilitate evaluations of quality of care in intensive care units
Background Improved access to healthcare in low- and middle-income countries (LMICs) has not equated to improved health outcomes. Absence or unsustained quality of care is partly to blame. Improving outcomes in intensive care units (ICUs) requires delivery of complex interventions by multiple specialties working in concert, and the simultaneous prevention of avoidable harms associated with the illness and the treatment interventions. Therefore, successful design and implementation of improvement interventions requires understanding of the behavioural, organisational, and external factors that determine care delivery and the likelihood of achieving sustained improvement. We aim to identify care processes that contribute to suboptimal clinical outcomes in ICUs located in LMICs and to establish barriers and enablers for improving the care processes. Methods Using rapid evaluation methods, we will use four data collection methods: 1) registry embedded indicators to assess quality of care processes and their associated outcomes; 2) process mapping to provide a preliminary framework to understand gaps between current and desired care practices; 3) structured observations of processes of interest identified from the process mapping and; 4) focus group discussions with stakeholders to identify barriers and enablers influencing the gap between current and desired care practices. We will also collect self-assessments of readiness for quality improvement. Data collection and analysis will be led by local stakeholders, performed in parallel and through an iterative process across eight countries: Kenya, India, Malaysia, Nepal, Pakistan, South Africa, Uganda and Vietnam. Conclusions The results of our study will provide essential information on where and how care processes can be improved to facilitate better quality of care to critically ill patients in LMICs; thus, reduce preventable mortality and morbidity in ICUs. Furthermore, understanding the rapid evaluation methods that will be used for this study will allow other researchers and healthcare professionals to carry out similar research in ICUs and other health services.
- Open Access
- 23 August 2023
- Published by Manuscript Technomedia LLP in Journal of Young Pharmacists
- Vol. 15 (3) , 397-405
Healthcare-Associated Infections: A Ten-Year Bibliometric Analysis
Rehab Ismaeil1*, Abdul Rahman Fata Nahas1, Norhidayah Binti Kamarudin2, Mohd Basri Mat Nor3, Usman Abubakar4 and Mohamad Haniki Nik Mohamed1 Author informationArticle notesCopyright and License informationPDFCitations Corresponding author. Correspondence: Mrs. Rehab Ismaeil, PhD Student, Department of Pharmacy Practice, Kulliyah of Pharmacy, International Islamic University Malaysia (IIUM), Jalan Sultan Ahmad Shah, Kuantan, Pahang, MALAYSIA. Email: rehabpharma81@gmail.com
- 23 August 2023
- Published by Manuscript Technomedia LLP in Journal of Young Pharmacists
- Vol. 15 (3) , 397-405
Open AccessHealthcare-Associated Infections: A Ten-Year Bibliometric Analysis
Rehab Ismaeil1*, Abdul Rahman Fata Nahas1, Norhidayah Binti Kamarudin2, Mohd Basri Mat Nor3, Usman Abubakar4 and Mohamad Haniki Nik Mohamed1 Author informationArticle notesCopyright and License informationPDFCitations Corresponding author. Correspondence: Mrs. Rehab Ismaeil, PhD Student, Department of Pharmacy Practice, Kulliyah of Pharmacy, International Islamic University Malaysia (IIUM), Jalan Sultan Ahmad Shah, Kuantan, Pahang, MALAYSIA. Email: rehabpharma81@gmail.com
- Open Access
- 21 July 2023
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 240, 107728
Virtual patient with temporal evolution for mechanical ventilation trial studies: A stochastic model approach
- 21 July 2023
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 240, 107728
Open AccessVirtual patient with temporal evolution for mechanical ventilation trial studies: A stochastic model approach